Menu
1 min read · estimated
APPROVED USE
What FDA approved
Single-agent treatment of advanced endometrial carcinoma identified as MSI-high or mismatch-repair-deficient by an FDA-approved test, after progression on prior systemic treatment in any setting when curative surgery or radiation is unsuitable.
LAMPGEN ANALYSIS
Why it matters
This defines an endometrial-specific monotherapy pathway based on MSI or mismatch repair status.
What research teams should watch
Capture the biomarker report, progression on prior therapy, and the decision about local curative treatment.
PRIMARY RECORDS